Drugs / TSD-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03081858 | May 2018 → Aug 2020 | non-invasive bladder urothelial carcinoma | Lipac Oncology LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-05-18 | TesoRx Pharma, LLC | Results TesoRx Subsidiary LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer tesorx.com ↗
Trial results showed 100% (6/6) of patients treated with Transurethral Resection of Bladder Tumor (TURBT) and LiPax achieved a complete response three, six and nine months after the start of therapy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-05-18 | TesoRx Pharma, LLC | TesoRx Subsidiary LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer tesorx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03081858 ↗ |